Straumann Group reported CHF 655 million fourth-quarter revenue, beating analyst estimates and delivering margins in line with guidance. However, the Swiss dental implants maker warned of continued pressure in China, where sales declined 12.8% organically. The company attributed the weakness to delayed procurement processes and distributor destocking ahead of the next volume-based procurement cycle.

While Europe and North America drove strength, Latin America posted robust growth. Full-year revenue reached CHF 2.6 billion, up 8.9% organically, though the board noted market volatility ahead. CEO Guillaume Daniellot highlighted market share gains as a key driver of the results. Free cash flow for 2025 fell to CHF 290 million from CHF 373 million, reflecting higher capital expenditure.

The board proposed a dividend increase to CHF 1 per share. Straumann expects high single-digit organic revenue growth in 2026 but cautioned that margin improvement will be volatile. The results underscore the challenge of sustaining growth amid persistent headwinds in China.